WFRF:(Myhr Eriksson Kristina)
Search: WFRF:(Myhr Eriksson Kristina) > Successful tyrosine...
- 4 of 16
- Previous record
- Next record
- To hitlist
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
-
- Flygt, Hjalmar (author)
- Uppsala universitet,Hematologi,Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden,Univ Hosp, Sweden; Univ Hosp, Sweden
-
- Sandin, Fredrik (author)
- Reg Canc Ctr, Uppsala, Sweden.,Regional Cancer Centre, Uppsala-Örebro, Sweden
-
- Dahlén, Torsten (author)
- Karolinska Institutet,Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.
- show more...
- show less...
- (creator_code:org_t)
- 2021-03-30
- 2021
- English.
- In: British Journal of Haematology. - : John Wiley & Sons. - 0007-1048 .- 1365-2141. ; 193:5, s. 915-921
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (>= 1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4 center dot 8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41 center dot 1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- chronic myeloid leukaemia
- BCR‐
- ABL
- tyrosine kinase inhibitor
- discontinuation
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- British Journal of Haematology (Search for host publication in LIBRIS)
To the university's database
- 4 of 16
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Flygt, Hjalmar
- Sandin, Fredrik
- Dahlén, Torsten
- Dreimane, Arta
- Lübking, Anna
- Markevärn, Berit
- show more...
- Myhr-Eriksson, K ...
- Olsson, Karin
- Olsson-Strömberg ...
- Själander, Ander ...
- Söderlund, Stina
- Wennström, Lovis ...
- Wadenvik, Hans
- Stenke, Leif
- Höglund, Martin
- Richter, Johan
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
- Articles in the publication
- British Journal ...
- By the university
- Uppsala University
- Umeå University
- Karolinska Institutet
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
